Clinical Trial Update: The Safety and Efficacy of SYD-101 in Children With Myopia [Phase 3]

View source ↗

Summary

Phase 3 trial of SYD-101 in children with myopia has been completed. The update reports on safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• SYD-101

Snippet

Sponsor: Sydnexis, Inc. | Conditions: Nearsightedness, Near Sightedness | Phase 3 | Status: COMPLETED